Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024996953> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2024996953 abstract "CTRC-AACR San Antonio Breast Cancer Symposium: 2008 AbstractsAbstract #2074 Background: In vitro work implicates c-Src in breast cancer. However there is little evidence to support this in clinical specimens. Activation of Src family members are associated with phosphorylation at two different tyrosine sites Y419: the classical activation site and Y215, known to induce a 50-fold increase in activation. We have analysed a cohort of human breast cancers to establish if expression levels of 2 Src family members (c-Src and Lyn) are associated with survival and whether this is dependent on site of activation. Methods: Tissue microarrays were constructed from 895 breast cancer tumors. Median follow up was 6 years with 229 breast cancer specific deaths. Immunohistochemistry was performed using antibodies to c-Src, Lyn, pSrc419 and pSrc215 (antibodies to Y419 and Y215 will detect phosphorylation of either c-Src and Lyn). Expression was assessed by two independent scorers. All statistical calculations were performed using SPSS 15. Results: Membrane expression of c-Src and Lyn was rarely observed. However, cytoplasmic expression of c-Src and Lyn was frequently observed and further results presented relate to this site. High expression levels of c-Src but not Lyn were associated with HER2 positivity (p=0.001) and ER negativity (p<0.001). High c-Src expression was associated with a poor outcome. In direct contrast pSrc215 was associated with improved outcome on univariate and multivariate analysis. Antibodies to phosphorylation sites will detect both activated c-Src and Lyn (and other family members). The individual impact of phosphorylation on clinical outcome was determined by categorising expression based on overexpression of c-Src or Lyn in combination with activation at each site. ![][1] Discussion: Our findings demonstrate that phosphorylation of c-Src at Y419 is associated with poor prognosis in breast cancer. In contrast phosphorylation at Y215 was independently associated with better outcome. Further work is ongoing to explore our hypothesis that: 1. phosphorylation at 215 'deactivates' c-Src or desensitizes downstream pathways or, 2. that activation of Lyn or other Src family members at 215 is responsible for good outcome. If confirmed, these results strongly suggest that commercial development of highly specific Src inhibitors is necessary and that these will require appropriate patient selection.Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2074. [1]: /embed/graphic-1.gif" @default.
- W2024996953 created "2016-06-24" @default.
- W2024996953 creator A5004544027 @default.
- W2024996953 creator A5011548408 @default.
- W2024996953 creator A5023115832 @default.
- W2024996953 creator A5026012372 @default.
- W2024996953 creator A5026280980 @default.
- W2024996953 creator A5048208263 @default.
- W2024996953 creator A5049264288 @default.
- W2024996953 creator A5064469818 @default.
- W2024996953 date "2009-01-15" @default.
- W2024996953 modified "2023-10-01" @default.
- W2024996953 title "Role of Src family members in breast cancer-dependent on site of phosphorylation." @default.
- W2024996953 doi "https://doi.org/10.1158/0008-5472.sabcs-2074" @default.
- W2024996953 hasPublicationYear "2009" @default.
- W2024996953 type Work @default.
- W2024996953 sameAs 2024996953 @default.
- W2024996953 citedByCount "0" @default.
- W2024996953 crossrefType "proceedings-article" @default.
- W2024996953 hasAuthorship W2024996953A5004544027 @default.
- W2024996953 hasAuthorship W2024996953A5011548408 @default.
- W2024996953 hasAuthorship W2024996953A5023115832 @default.
- W2024996953 hasAuthorship W2024996953A5026012372 @default.
- W2024996953 hasAuthorship W2024996953A5026280980 @default.
- W2024996953 hasAuthorship W2024996953A5048208263 @default.
- W2024996953 hasAuthorship W2024996953A5049264288 @default.
- W2024996953 hasAuthorship W2024996953A5064469818 @default.
- W2024996953 hasConcept C108636557 @default.
- W2024996953 hasConcept C11960822 @default.
- W2024996953 hasConcept C121608353 @default.
- W2024996953 hasConcept C126322002 @default.
- W2024996953 hasConcept C143998085 @default.
- W2024996953 hasConcept C170493617 @default.
- W2024996953 hasConcept C175818844 @default.
- W2024996953 hasConcept C183141693 @default.
- W2024996953 hasConcept C197153747 @default.
- W2024996953 hasConcept C204232928 @default.
- W2024996953 hasConcept C502942594 @default.
- W2024996953 hasConcept C530470458 @default.
- W2024996953 hasConcept C54355233 @default.
- W2024996953 hasConcept C71924100 @default.
- W2024996953 hasConcept C86803240 @default.
- W2024996953 hasConceptScore W2024996953C108636557 @default.
- W2024996953 hasConceptScore W2024996953C11960822 @default.
- W2024996953 hasConceptScore W2024996953C121608353 @default.
- W2024996953 hasConceptScore W2024996953C126322002 @default.
- W2024996953 hasConceptScore W2024996953C143998085 @default.
- W2024996953 hasConceptScore W2024996953C170493617 @default.
- W2024996953 hasConceptScore W2024996953C175818844 @default.
- W2024996953 hasConceptScore W2024996953C183141693 @default.
- W2024996953 hasConceptScore W2024996953C197153747 @default.
- W2024996953 hasConceptScore W2024996953C204232928 @default.
- W2024996953 hasConceptScore W2024996953C502942594 @default.
- W2024996953 hasConceptScore W2024996953C530470458 @default.
- W2024996953 hasConceptScore W2024996953C54355233 @default.
- W2024996953 hasConceptScore W2024996953C71924100 @default.
- W2024996953 hasConceptScore W2024996953C86803240 @default.
- W2024996953 hasLocation W20249969531 @default.
- W2024996953 hasOpenAccess W2024996953 @default.
- W2024996953 hasPrimaryLocation W20249969531 @default.
- W2024996953 hasRelatedWork W1564903357 @default.
- W2024996953 hasRelatedWork W1811546407 @default.
- W2024996953 hasRelatedWork W1967818195 @default.
- W2024996953 hasRelatedWork W1989053720 @default.
- W2024996953 hasRelatedWork W2004458895 @default.
- W2024996953 hasRelatedWork W2009411841 @default.
- W2024996953 hasRelatedWork W2020668404 @default.
- W2024996953 hasRelatedWork W2067228821 @default.
- W2024996953 hasRelatedWork W2102658672 @default.
- W2024996953 hasRelatedWork W2118767742 @default.
- W2024996953 hasRelatedWork W2143905730 @default.
- W2024996953 hasRelatedWork W2145355816 @default.
- W2024996953 hasRelatedWork W2329198850 @default.
- W2024996953 hasRelatedWork W2548554350 @default.
- W2024996953 hasRelatedWork W2789350247 @default.
- W2024996953 hasRelatedWork W2899706924 @default.
- W2024996953 hasRelatedWork W2981738178 @default.
- W2024996953 hasRelatedWork W2999823665 @default.
- W2024996953 hasRelatedWork W3123856817 @default.
- W2024996953 hasRelatedWork W949967083 @default.
- W2024996953 isParatext "false" @default.
- W2024996953 isRetracted "false" @default.
- W2024996953 magId "2024996953" @default.
- W2024996953 workType "article" @default.
!["CTRC-AACR San Antonio Breast Cancer Symposium: 2008 AbstractsAbstract #2074 Background: In vitro work implicates c-Src in breast cancer. However there is little evidence to support this in clinical specimens. Activation of Src family members are associated with phosphorylation at two different tyrosine sites Y419: the classical activation site and Y215, known to induce a 50-fold increase in activation. We have analysed a cohort of human breast cancers to establish if expression levels of 2 Src family members (c-Src and Lyn) are associated with survival and whether this is dependent on site of activation. Methods: Tissue microarrays were constructed from 895 breast cancer tumors. Median follow up was 6 years with 229 breast cancer specific deaths. Immunohistochemistry was performed using antibodies to c-Src, Lyn, pSrc419 and pSrc215 (antibodies to Y419 and Y215 will detect phosphorylation of either c-Src and Lyn). Expression was assessed by two independent scorers. All statistical calculations were performed using SPSS 15. Results: Membrane expression of c-Src and Lyn was rarely observed. However, cytoplasmic expression of c-Src and Lyn was frequently observed and further results presented relate to this site. High expression levels of c-Src but not Lyn were associated with HER2 positivity (p=0.001) and ER negativity (p<0.001). High c-Src expression was associated with a poor outcome. In direct contrast pSrc215 was associated with improved outcome on univariate and multivariate analysis. Antibodies to phosphorylation sites will detect both activated c-Src and Lyn (and other family members). The individual impact of phosphorylation on clinical outcome was determined by categorising expression based on overexpression of c-Src or Lyn in combination with activation at each site. ![][1] Discussion: Our findings demonstrate that phosphorylation of c-Src at Y419 is associated with poor prognosis in breast cancer. In contrast phosphorylation at Y215 was independently associated with better outcome. Further work is ongoing to explore our hypothesis that: 1. phosphorylation at 215 'deactivates' c-Src or desensitizes downstream pathways or, 2. that activation of Lyn or other Src family members at 215 is responsible for good outcome. If confirmed, these results strongly suggest that commercial development of highly specific Src inhibitors is necessary and that these will require appropriate patient selection.Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2074. [1]: /embed/graphic-1.gif"](?object=%22CTRC-AACR%20San%20Antonio%20Breast%20Cancer%20Symposium%3A%202008%20AbstractsAbstract%20%232074%20Background%3A%20In%20vitro%20work%20implicates%20c-Src%20in%20breast%20cancer.%20However%20there%20is%20little%20evidence%20to%20support%20this%20in%20clinical%20specimens.%20Activation%20of%20Src%20family%20members%20are%20associated%20with%20phosphorylation%20at%20two%20different%20tyrosine%20sites%20Y419%3A%20the%20classical%20activation%20site%20and%20Y215%2C%20known%20to%20induce%20a%2050-fold%20increase%20in%20activation.%20We%20have%20analysed%20a%20cohort%20of%20human%20breast%20cancers%20to%20establish%20if%20expression%20levels%20of%202%20Src%20family%20members%20(c-Src%20and%20Lyn)%20are%20associated%20with%20survival%20and%20whether%20this%20is%20dependent%20on%20site%20of%20activation.%20Methods%3A%20Tissue%20microarrays%20were%20constructed%20from%20895%20breast%20cancer%20tumors.%20Median%20follow%20up%20was%206%20years%20with%20229%20breast%20cancer%20specific%20deaths.%20Immunohistochemistry%20was%20performed%20using%20antibodies%20to%20c-Src%2C%20Lyn%2C%20pSrc419%20and%20pSrc215%20(antibodies%20to%20Y419%20and%20Y215%20will%20detect%20phosphorylation%20of%20either%20c-Src%20and%20Lyn).%20Expression%20was%20assessed%20by%20two%20independent%20scorers.%20All%20statistical%20calculations%20were%20performed%20using%20SPSS%2015.%20Results%3A%20Membrane%20expression%20of%20c-Src%20and%20Lyn%20was%20rarely%20observed.%20However%2C%20cytoplasmic%20expression%20of%20c-Src%20and%20Lyn%20was%20frequently%20observed%20and%20further%20results%20presented%20relate%20to%20this%20site.%20High%20expression%20levels%20of%20c-Src%20but%20not%20Lyn%20were%20associated%20with%20HER2%20positivity%20(p%3D0.001)%20and%20ER%20negativity%20(p%3C0.001).%20High%20c-Src%20expression%20was%20associated%20with%20a%20poor%20outcome.%20In%20direct%20contrast%20pSrc215%20was%20associated%20with%20improved%20outcome%20on%20univariate%20and%20multivariate%20analysis.%20Antibodies%20to%20phosphorylation%20sites%20will%20detect%20both%20activated%20c-Src%20and%20Lyn%20(and%20other%20family%20members).%20The%20individual%20impact%20of%20phosphorylation%20on%20clinical%20outcome%20was%20determined%20by%20categorising%20expression%20based%20on%20overexpression%20of%20c-Src%20or%20Lyn%20in%20combination%20with%20activation%20at%20each%20site.%20!%5B%5D%5B1%5D%20Discussion%3A%20Our%20findings%20demonstrate%20that%20phosphorylation%20of%20c-Src%20at%20Y419%20is%20associated%20with%20poor%20prognosis%20in%20breast%20cancer.%20In%20contrast%20phosphorylation%20at%20Y215%20was%20independently%20associated%20with%20better%20outcome.%20Further%20work%20is%20ongoing%20to%20explore%20our%20hypothesis%20that%3A%201.%20phosphorylation%20at%20215%20'deactivates'%20c-Src%20or%20desensitizes%20downstream%20pathways%20or%2C%202.%20that%20activation%20of%20Lyn%20or%20other%20Src%20family%20members%20at%20215%20is%20responsible%20for%20good%20outcome.%20If%20confirmed%2C%20these%20results%20strongly%20suggest%20that%20commercial%20development%20of%20highly%20specific%20Src%20inhibitors%20is%20necessary%20and%20that%20these%20will%20require%20appropriate%20patient%20selection.Citation%20Information%3A%20Cancer%20Res%202009%3B69(2%20Suppl)%3AAbstract%20nr%202074.%20%5B1%5D%3A%20%2Fembed%2Fgraphic-1.gif%22){kind=link}